FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Kidney Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Systematic Review and Bayesian Network Meta-Analysis. PMID 36999976 · Clin J Am Soc Nephrol · 2023-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHY: Review of Salient Functional Outcomes and Perspective. PMID 36996460 · Retina · 2023-Jul-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. PMID 36596347 · Int J Radiat Oncol Biol Phys · 2023-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) Results. PMID 35833413 · Ann Surg · 2023-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China. PMID 37601010 · Res Pract Thromb Haemost · 2023-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. PMID 37547039 · Lancet Reg Health West Pac · 2023-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide-Based Regimens. PMID 37520420 · Open Forum Infect Dis · 2023-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cicaderma® in radiation-related dermatitis of breast cancer: Results from the multicentric randomised phase III CICA-RT. PMID 37441546 · Clin Transl Radiat Oncol · 2023-Jul The study is an oncology randomized phase III trial with original results, but it does not meet the core eligibility criteria: it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) and lacks a drug-containing intervention (Cicaderma® is a topical non-drug product, and the comparator is standard non-drug care). The primary endpoint is prevention of radiation dermatitis, which is a toxicity/safety outcome, not an efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial. PMID 37441544 · Clin Transl Radiat Oncol · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients. PMID 37427293 · Kidney Med · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients. PMID 37427292 · Kidney Med · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study. PMID 37427146 · Hemasphere · 2023-Jul Explicitly identified as an international phase-3 randomized trial with drug intervention (R-CHOP) and primary/key secondary time-to-event efficacy endpoints (EFS, PFS, OS). Results are from the original trial report. |
H
S
B
|
严格 v3 独有 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 9 Panel · risk visible |
| Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial. PMID 37427145 · Hemasphere · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). PMID 37422371 · Eur Urol Focus · 2023-Jul The record describes the design and rationale of a Phase 3 randomized trial in human oncology with a drug intervention, but does not report any time-to-event efficacy results, Kaplan-Meier curves, or hazard ratios. Therefore, eligibility cannot be determined. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Current progress in perioperative chemotherapy for biliary tract cancer. PMID 37416744 · Ann Gastroenterol Surg · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. PMID 37404971 · Focus (Am Psychiatr Publ) · 2023-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. PMID 37404773 · Hemasphere · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 4 Figure · 9 Panel · risk visible |
| In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events. PMID 37399559 · Ann Intern Med · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| In ischemic stroke, adding EVT to usual care at 6 to 24 h improved functional status at 90 d. PMID 37399551 · Ann Intern Med · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. PMID 37355760 · Nat Med · 2023-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience. PMID 37351971 · Anticancer Res · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Endobronchial indocyanine green instillation to identify the intersegmental plane for successful segmentectomy. PMID 37342249 · Respirol Case Rep · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review. PMID 37336142 · Cancer Treat Rev · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. PMID 37334673 · Future Oncol · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. PMID 37329769 · J Geriatr Oncol · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden. PMID 37173513 · Appl Health Econ Health Policy · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis. PMID 37130463 · Eur J Cancer · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparison of Two Manufacturing Processes of Daprodustat for Bioequivalence and Dissolution in Healthy Volunteers: A Randomized Crossover Study. PMID 37125459 · Clin Pharmacol Drug Dev · 2023-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France. PMID 37071263 · Pharmacoecon Open · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials. PMID 37052803 · Epilepsia · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. PMID 37005966 · Breast Cancer · 2023-Jul 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
S
B
|
严格 v3 独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol. PMID 36871111 · Ther Innov Regul Sci · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies. PMID 36740580 · Br J Clin Pharmacol · 2023-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol. PMID 36655938 · Int J Stroke · 2023-Jul 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. PMID 36367094 · Ann Pharmacother · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus. PMID 36343847 · Clin Gastroenterol Hepatol · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. PMID 36310299 · J Cancer Res Clin Oncol · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Timing of Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. PMID 35762354 · Can J Neurol Sci · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang. PMID 34172504 · Ann Rheum Dis · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial'. PMID 34172501 · Ann Rheum Dis · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. PMID 36851177 · Vaccines (Basel) · 2023-Jan-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Advances in cancer vaccines for immunotherapy of prostate cancer. PMID 36935188 · Zhong Nan Da Xue Xue Bao Yi Xue Ban · 2023-Jan-28 This is a review article, not an original report of a randomized trial. It mentions trials but does not present primary or secondary time-to-event efficacy results from a specific drug-containing intervention trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer. PMID 36705526 · Future Oncol · 2023-Jan-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 36832337 · Children (Basel) · 2023-Jan-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis. PMID 36768562 · Int J Mol Sci · 2023-Jan-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. Reply. PMID 36652365 · N Engl J Med · 2023-Jan-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Phlebotomy resulting in controlled hypovolemia to prevent blood loss in major hepatic resections (PRICE-2): study protocol for a phase 3 randomized controlled trial. PMID 36653812 · Trials · 2023-Jan-18 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). PMID 36522265 · Vaccine · 2023-Jan-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach. PMID 36760246 · Ann Transl Med · 2023-Jan-15 This is a review article (report_type: 'other') that proposes reporting guidelines based on a review of oncology trials. It is not an original clinical trial report with a drug intervention and a time-to-event efficacy endpoint. Therefore, it is ineligible. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability. PMID 36273682 · J Affect Disord · 2023-Jan-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |